<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This cooperative study assessed prognostic factors for overall survival (OS) and risk of transformation to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) in 541 patients with de novo <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and deletion 5q </plain></SENT>
<SENT sid="1" pm="."><plain>Additional chromosomal abnormalities were strongly related to different patients' characteristics </plain></SENT>
<SENT sid="2" pm="."><plain>In multivariate analysis, the most important predictors of both OS and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> transformation risk were number of chromosomal abnormalities (P&lt;0.001 for both outcomes), platelet count (P&lt;0.001 and P=0.001, respectively) and proportion of bone marrow blasts (P&lt;0.001 and P=0.016, respectively) </plain></SENT>
<SENT sid="3" pm="."><plain>The number of chromosomal abnormalities defined three risk categories for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> transformation (del(5q), del(5q)+1 and del(5q)+ ≥ 2 abnormalities) and two for OS (one group: del(5q) and del(5q)+1; and del(5q)+ ≥ 2 abnormalities, as the other one); with a median survival time of 58.0 and 6.8 months, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Platelet count (P=0.001) and age (P=0.034) predicted OS in patients with '<z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q-syndrome</z:e>' </plain></SENT>
<SENT sid="5" pm="."><plain>This study demonstrates the importance of additional chromosomal abnormalities in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with deletion 5q, challenges the current '<z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q-syndrome</z:e>' definition and constitutes a useful reference series to properly analyze the results of clinical trials in these patients </plain></SENT>
</text></document>